Treatment Delay for Lung Cancer Patients
Raymond Osarogiagbon, MBBS and Nicolas Faris, MDiv led a group of researchers from Baptist Cancer Center and the University of Memphis in Tennessee, who reviewed hospital records for all patients who underwent surgery for suspected lung cancer at Baptist Memorial Hospital between January 2009 and June 2013. They wanted to know how much time it takes to begin care and what steps are taken to determine appropriate treatment for these patients.
“It takes too long for patients who have suspected lung cancer to get final treatment, and too many patients skip vital steps needed to decide the best possible treatment,” Dr. Osarogiagbon points out. “This delay in treatment can cause the cancer to advance and reduce the odds of survival for the patient.”
Of the 614 eligible patients included in the analysis, 27 percent had no preoperative diagnostic procedure, 22 percent did not have an imaging scan to stage the cancer, and 88 percent did not have an invasive staging test. Notably, only 1 in 10 patients (10 percent) had the recommended combination of three staging tests — computed tomography (CT) scan, positron emission tomography (PET)/CT scan, and an invasive test — before surgery.
Overall, results also showed that it took a month and a half to more than six months for many patients to undergo surgery after an initial x-ray displayed signs of possible lung cancer.
“Lung cancer care is complicated, and all key specialists must be actively engaged early on with each patient to determine the best sequence of tests and treatment for each individual,” Dr. Osarogiagbon says.
Faris also notes that quality matters at every step in the lung cancer treatment process. “Patients should feel comfortable taking an active role in their treatment process and ask a lot of questions — find out what treatment is right for them, why that option is the best, and what steps they can take to be better prepared for treatment,” he says.
The study is part of an ongoing prospective process-of-care analysis to examine factors associated with deviation from optimal care delivery for both surgical and non-surgical patients.
Source: Society of Thoracic Surgeons
Image credit: Pixabay
Published on : Thu, 30 Jul 2015
Better detection. Clinically superior. Low dose.** What if we could find breast cancers earlier? See lesions more clearly? Reduce the number of unnecessary biopsies? Questions like these inspired Hologic researchers and scientists to develop Hologic...
The SonoSite SII features a new touchscreen user interface with a clinician-driven menu logic that adaptively adjusts to your imaging needs – “what you need, is what you see”. An embedded dual transducer connector allows you to quickly switch between...
About the Affirm® breast biopsy guidance system Our passion to offer innovative interventional tools that advance breast health fueled the development of the Affirm breast biopsy guidance system. This simple add-on to any Hologic 3D Mammography™-capable...
RDM: the DACS for building a Low-Dose Culture RDM is a software solution for collecting, controlling and analyzing radiation doses delivered to patients during medical imaging examinations. It helps improve clinical practices and optimize doses....
Expertly designed to optimize productivity ARIETTA 65 has been designed to perform quick and precise diagnosis in general imaging without compromising on productivity and workflow. This ultrasound platform combines productivity, enhanced tools...